Evaluating the Combination of Radioimmunotherapy and Immunotherapy in a Melanoma Mouse Model
Abstract
:1. Introduction
2. Results
3. Discussion
4. Materials and Methods
Author Contributions
Funding
Conflicts of Interest
References
- Marshall, H.T.; Djamgoz, M.B.A. Immuno-Oncology: Emerging Targets and Combination Therapies. Front. Oncol. 2018, 8, 315. [Google Scholar] [CrossRef] [PubMed]
- Ajina, R.; Zahavi, D.J.; Zhang, Y.W.; Weiner, L.M. Overcoming Malignant Cell-Based Mechanisms of Resistance to Immune Checkpoint Blockade Antibodies. In Seminars in Cancer Biology; Academic Press: Cambridge, MA, USA, 2019. [Google Scholar] [CrossRef]
- Syngeneic Mouse Models, Charles River. Available online: https://www.criver.com/products-services/discovery-services/vivo-pharmacology/oncology-pharmacology-models/syngeneic-models?region=3601 (accessed on 31 December 2019).
- Wolchok, J.D.; Chiarion-Sileni, V.; Gonzalez, R.; Rutkowski, P.; Grob, J.J.; Cowey, L.; Lao, C.D.; Wagstaff, M.P.H.J.; Schadendorf, D.; Ferrucci, P.F.; et al. Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma. N. Engl. J. Med. 2017, 377, 1345–1356. [Google Scholar] [CrossRef] [PubMed]
- Smaglo, B.G.; Aldeghaither, D.; Weiner, L.M. The development of immunoconjugates for targeted cancer therapy. Nat. Rev. Clin. Oncol. 2014, 11, 637–648. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Pouget, J.P.; Navarro-Teulon, I.; Bardies, M.; Chouin, N.; Cartron, G.; Pelegrin, A.; Azria, D. Clinical radioimmunotherapy—The role of radiobiology. Nat. Rev. Clin. Oncol. 2011, 8, 720–734. [Google Scholar] [CrossRef] [PubMed]
- Sharabi, A.B.; Lim, M.; DeWeese, T.L.; Drake, C.G. Radiation and checkpoint blockade immunotherapy: Radiosensitisation and potential mechanisms of synergy. Lancet Oncol. 2015, 16, e498–e509. [Google Scholar] [CrossRef]
- Schoenhals, J.E.; Skrepnik, T.; Selek, U.; Cortez, M.A.; Li, A.; Welsh, J.W. Optimizing Radiotherapy with Immunotherapeutic Approaches. Adv. Exp. Med. Biol. 2017, 995, 53–71. [Google Scholar] [PubMed]
- Klein, M.; Lotem, M.; Peretz, T.; Zwas, S.T.; Mizrachi, S.; Liberman, Y.; Chisin, R.; Schachter, J.; Ron, I.G.; Iosilevsky, G.; et al. Safety and efficacy of 188-rhenium-labeled antibody to melanin in patients with metastatic melanoma. J. Skin Cancer 2013, 2013, 828329. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Allen, K.J.H.; Jiao, R.; Malo, M.E.; Frank, C.; Fisher, D.R.; Rickles, D.; Dadachova, E. Comparative Radioimmunotherapy of Experimental Melanoma with Novel Humanized Antibody to Melanin Labeled with 213Bismuth and 177Lutetium. Pharmaceutics 2019, 11, 348. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- De Bruyn, M.; Rybczynska, A.A.; Wei, Y.; Schwenkert, M.; Fey, G.H.; Dierckx, R.A.; van Waarde, A.; Helfrich, W.; Bremer, E. Melanoma-associated Chondroitin Sulfate Proteoglycan (MCSP)-targeted delivery of soluble TRAIL potently inhibits melanoma outgrowth in vitro and in vivo. Mol. Cancer 2010, 9, 301. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Dadachova, E.; Nosanchuk, J.D.; Shi, L.; Schweitzer, A.D.; Frenkel, A.; Nosanchuk, J.S.; Casadevall, A. Dead cells in melanoma tumors provide abundant antigen for targeted delivery of ionizing radiation by a monoclonal antibody to melanin. Proc. Natl. Acad. Sci. USA 2004, 101, 14865–14870. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- García-Barros, M.; Thin, T.H.; Maj, J.; Cordon-Cardo, C.; Haimovitz-Friedman, A.; Fuks, Z.; Kolesnick, R. Impact of stromal sensitivity on radiation response of tumors implanted in SCID hosts revisited. Cancer Res. 2010, 70, 8179–8186. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Kuzu, O.F.; Nguyen, F.D.; Noory, M.A.; Sharma, A. Current State of Animal (Mouse) Modeling in Melanoma Research. Cancer Growth Metastasis 2015, 8, 81–94. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Hosoi, J.; Abe, E.; Suda, T.; Kuroki, T. Regulation of melanin synthesis of B16 mouse melanoma cells by 1 alpha, 25-dihydroxyvitamin D3 and retinoic acid. Cancer Res. 1985, 45, 1474–1478. [Google Scholar] [PubMed]
- Chung, S.; Lim, G.J.; Lee, J.Y. Quantitative analysis of melanin content in a three-dimensional melanoma cell culture. Sci. Rep. 2019, 9, 780. [Google Scholar] [CrossRef] [PubMed]
- Teicher, B.A. Tumor Models in Cancer Research; Humana Press: New York, NY, USA; Dordrecht, The Netherlands; Heidelberg, Germany; London, UK, 2010. [Google Scholar]
- Kleffel, S.; Posch, C.; Barthel, S.R.; Mueller, H.; Schlapbach, C.; Guenova, E.; Elco, C.P.; Lee, N.; Juneja, V.R.; Zhan, Q.; et al. Melanoma Cell-Intrinsic PD-1 Receptor Functions Promote Tumor Growth. Cell 2015, 162, 1242–1256. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Deng, R.; Bumbaca, D.; Pastuskovas, C.V.; Boswell, C.A.; West, D.; Cowan, K.J.; Chiu, H.; McBride, J.; Johnson, C.; Xin, Y.; et al. Preclinical pharmacokinetics, pharmacodynamics, tissue distribution, and tumor penetration of anti-PD-L1 monoclonal antibody, an immune checkpoint inhibitor. MAbs 2016, 8, 593–603. [Google Scholar] [CrossRef] [PubMed]
- Taub, F.E.; Wright, S.; Guth, A. Combination checkpoint inhibitor therapy: Anti-PD1 and Beta-alethine lead to complete responses of melanoma in a syngeneic mouse model. Cancer Res. 2017, 77, 191. [Google Scholar]
- Arend, R.C. Strategy, Efficacy and Safety of Combination Egimens Using Immunotherapy. Available online: https://www.fda.gov/media/114603/download (accessed on 31 December 2019).
- Nosanchuk, J.D.; Jeyakumar, A.; Ray, A.; Revskaya, E.; Jiang, Z.; Bryan, R.A.; Allen, K.J.H.; Jiao, R.; Malo, M.E.; Gómez, B.L.; et al. Structure-function analysis and therapeutic efficacy of antibodies to fungal melanin for melanoma radioimmunotherapy. Sci. Rep. 2018, 8, 5466. [Google Scholar] [CrossRef] [PubMed]
- Allen, K.J.H.; Jiao, R.; Malo, M.E.; Frank, C.; Dadachova, E. Biodistribution of a Radiolabeled Antibody in Mice as an Approach to Evaluating Antibody Pharmacokinetics. Pharmaceutics 2018, 10, 262. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Cooper, Z.A.; Juneja, V.R.; Sage, P.T.; Frederick, D.T.; Piris, A.; Mitra, D.; Lo, J.A.; Hodi, F.S.; Freeman, G.J.; Bosenberg, M.W.; et al. Response to BRAF inhibition in melanoma is enhanced when combined with immune checkpoint blockade. Cancer Immunol. Res. 2014, 2, 643–654. [Google Scholar] [CrossRef] [PubMed] [Green Version]
© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
Share and Cite
Jiao, R.; Allen, K.J.H.; Malo, M.E.; Rickles, D.; Dadachova, E. Evaluating the Combination of Radioimmunotherapy and Immunotherapy in a Melanoma Mouse Model. Int. J. Mol. Sci. 2020, 21, 773. https://doi.org/10.3390/ijms21030773
Jiao R, Allen KJH, Malo ME, Rickles D, Dadachova E. Evaluating the Combination of Radioimmunotherapy and Immunotherapy in a Melanoma Mouse Model. International Journal of Molecular Sciences. 2020; 21(3):773. https://doi.org/10.3390/ijms21030773
Chicago/Turabian StyleJiao, R., K.J.H. Allen, M.E. Malo, D. Rickles, and E. Dadachova. 2020. "Evaluating the Combination of Radioimmunotherapy and Immunotherapy in a Melanoma Mouse Model" International Journal of Molecular Sciences 21, no. 3: 773. https://doi.org/10.3390/ijms21030773